Novavax launches COVID-19 vaccine trial in South Africa


Novavax NVAX,
+ 9,92%
said it was starting a Phase 2b clinical trial in South Africa to assess the effectiveness of NVX-CoV2373, its COVID-19 vaccine candidate. The Bill & Melinda Gates Foundation is providing a $ 15 million grant for a trial, said Novavax, which agreed last week to sell its vaccine to the British government if successful. “Because South Africa is experiencing a winter outbreak of COVID-19 disease, this important phase 2b clinical trial has the potential to provide an early indication of efficacy, as well as additional safety and immunogenicity data. for NVX-CoV2373, ”said Gregory Glenn, president of research and development at Novavax.


Please enter your comment!
Please enter your name here